A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters
The emergence of COVID-19 has led to a pandemic that has caused millions of cases of disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir and dexamethasone have demonstrated limited efficacy, only slightly reducing disease burden, thus novel approaches for clin...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2020.614256/full |
| id |
doaj-be1fe2185a46453ea75f29eac50223c5 |
|---|---|
| record_format |
Article |
| spelling |
doaj-be1fe2185a46453ea75f29eac50223c52020-12-18T05:07:26ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-12-011110.3389/fimmu.2020.614256614256A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian HamstersAnna C. Fagre0John Manhard1Rachel Adams2Miles Eckley3Shijun Zhan4Juliette Lewis5Savannah M. Rocha6Catherine Woods7Karina Kuo8Wuxiang Liao9Lin Li10Adam Corper11Dilip Challa12Emily Mount13Christine Tumanut14Ronald B. Tjalkens15Tawfik Aboellail16Xiaomin Fan17Tony Schountz18Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesAvantGen, Inc. San Diego, CA, United StatesAvantGen, Inc. San Diego, CA, United StatesDepartment of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesDepartment of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesDepartment of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesDepartment of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesAvantGen, Inc. San Diego, CA, United StatesAvantGen, Inc. San Diego, CA, United StatesAvantGen, Inc. San Diego, CA, United StatesAvantGen, Inc. San Diego, CA, United StatesAvantGen, Inc. San Diego, CA, United StatesAvantGen, Inc. San Diego, CA, United StatesAvantGen, Inc. San Diego, CA, United StatesAvantGen, Inc. San Diego, CA, United StatesDepartment of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesDepartment of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesAvantGen, Inc. San Diego, CA, United StatesDepartment of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesThe emergence of COVID-19 has led to a pandemic that has caused millions of cases of disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir and dexamethasone have demonstrated limited efficacy, only slightly reducing disease burden, thus novel approaches for clinical management of COVID-19 are needed. We identified a panel of human monoclonal antibody clones from a yeast display library with specificity to the SARS-CoV-2 spike protein receptor binding domain that neutralized the virus in vitro. Administration of the lead antibody clone to Syrian hamsters challenged with SARS-CoV-2 significantly reduced viral load and histopathology score in the lungs. Moreover, the antibody interrupted monocyte infiltration into the lungs, which may have contributed to the reduction of disease severity by limiting immunopathological exacerbation. The use of this antibody could provide an important therapy for treatment of COVID-19 patients.https://www.frontiersin.org/articles/10.3389/fimmu.2020.614256/fullCOVIDmonoclonal AbSARS-CoV-2therapeutic antibodiescoronavirus |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Anna C. Fagre John Manhard Rachel Adams Miles Eckley Shijun Zhan Juliette Lewis Savannah M. Rocha Catherine Woods Karina Kuo Wuxiang Liao Lin Li Adam Corper Dilip Challa Emily Mount Christine Tumanut Ronald B. Tjalkens Tawfik Aboellail Xiaomin Fan Tony Schountz |
| spellingShingle |
Anna C. Fagre John Manhard Rachel Adams Miles Eckley Shijun Zhan Juliette Lewis Savannah M. Rocha Catherine Woods Karina Kuo Wuxiang Liao Lin Li Adam Corper Dilip Challa Emily Mount Christine Tumanut Ronald B. Tjalkens Tawfik Aboellail Xiaomin Fan Tony Schountz A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters Frontiers in Immunology COVID monoclonal Ab SARS-CoV-2 therapeutic antibodies coronavirus |
| author_facet |
Anna C. Fagre John Manhard Rachel Adams Miles Eckley Shijun Zhan Juliette Lewis Savannah M. Rocha Catherine Woods Karina Kuo Wuxiang Liao Lin Li Adam Corper Dilip Challa Emily Mount Christine Tumanut Ronald B. Tjalkens Tawfik Aboellail Xiaomin Fan Tony Schountz |
| author_sort |
Anna C. Fagre |
| title |
A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters |
| title_short |
A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters |
| title_full |
A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters |
| title_fullStr |
A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters |
| title_full_unstemmed |
A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters |
| title_sort |
potent sars-cov-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in syrian hamsters |
| publisher |
Frontiers Media S.A. |
| series |
Frontiers in Immunology |
| issn |
1664-3224 |
| publishDate |
2020-12-01 |
| description |
The emergence of COVID-19 has led to a pandemic that has caused millions of cases of disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir and dexamethasone have demonstrated limited efficacy, only slightly reducing disease burden, thus novel approaches for clinical management of COVID-19 are needed. We identified a panel of human monoclonal antibody clones from a yeast display library with specificity to the SARS-CoV-2 spike protein receptor binding domain that neutralized the virus in vitro. Administration of the lead antibody clone to Syrian hamsters challenged with SARS-CoV-2 significantly reduced viral load and histopathology score in the lungs. Moreover, the antibody interrupted monocyte infiltration into the lungs, which may have contributed to the reduction of disease severity by limiting immunopathological exacerbation. The use of this antibody could provide an important therapy for treatment of COVID-19 patients. |
| topic |
COVID monoclonal Ab SARS-CoV-2 therapeutic antibodies coronavirus |
| url |
https://www.frontiersin.org/articles/10.3389/fimmu.2020.614256/full |
| work_keys_str_mv |
AT annacfagre apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT johnmanhard apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT racheladams apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT mileseckley apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT shijunzhan apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT juliettelewis apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT savannahmrocha apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT catherinewoods apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT karinakuo apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT wuxiangliao apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT linli apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT adamcorper apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT dilipchalla apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT emilymount apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT christinetumanut apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT ronaldbtjalkens apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT tawfikaboellail apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT xiaominfan apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT tonyschountz apotentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT annacfagre potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT johnmanhard potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT racheladams potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT mileseckley potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT shijunzhan potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT juliettelewis potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT savannahmrocha potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT catherinewoods potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT karinakuo potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT wuxiangliao potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT linli potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT adamcorper potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT dilipchalla potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT emilymount potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT christinetumanut potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT ronaldbtjalkens potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT tawfikaboellail potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT xiaominfan potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters AT tonyschountz potentsarscov2neutralizinghumanmonoclonalantibodythatreducesviralburdenanddiseaseseverityinsyrianhamsters |
| _version_ |
1724378695474348032 |